SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as news circulates about the departure of a key FDA official, which the community believes removes a significant hurdle and could accelerate the approval path for their Duchenne Muscular Dystrophy (DMD) therapy, Deramiocel; this development, combined with upcoming Phase 3 data presentations, is intensifying short squeeze and buyout speculation.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure is surging as a key FDA official's departure and reports of a less invasive trial design for its Huntington's gene therapy ignite community hopes for accelerated approval, triggering a significant short squeeze after a week of regulatory setbacks.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is trending as escalating Middle East tensions and significant disruptions to the Strait of Hormuz drive oil prices to multi-year highs with historic weekly gains. Traders are fiercely debating whether this represents a sustainable "plumbing break" or an overextended "fear trade" ripe for a pullback, amidst discussions of potential US administration interventions to stabilize the market.

Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is founded on March 14, 2024 and is headquartered in Jackson, WY.

Brand Engagement Network Inc

Brand Engagement Network Inc. (BNAI) is trending after completing an AI licensing partnership in Africa, which, combined with its low float and extremely high cost-to-borrow, is fueling intense short squeeze speculation among traders. The community is actively discussing strong buy-side pressure and the stock's resilience amidst a broader red market, with many holding for significant upside.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum Holdings (LITE) is trending amid its S&P 500 inclusion and a significant strategic investment from NVIDIA, solidifying its critical position in AI infrastructure expansion. The community is actively discussing whether its high valuation is justified by its role in supplying advanced optical components, particularly in light of industry perspectives on optical versus copper solutions for data center connectivity.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending as the anticipated departure of a key FDA official fuels community speculation for a significantly softened regulatory landscape for gene therapies, with many expecting SRPT to follow recent rallies in comparable biotechs ahead of upcoming pivotal DM1 and FSHD data readouts.

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance Biotherapeutics is trending with surging volume, fueled by intense short-covering and bullish community sentiment. Investors are optimistic about a significant re-rating, citing recent analyst upgrades, M&A buzz in the oncology sector, and anticipated data readouts for its promising TIL therapy platform.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X Shares

Direxion Daily Semiconductor Bull 3X Shares

SOXL is facing extreme volatility, drawing polarized community sentiment between dip-buyers confident in long-term AI demand and short-sellers citing geopolitical concerns and the ETF's repeated failure to break key resistance. The leveraged semiconductor fund is seeing rapid swings, driven by mixed reactions to sector earnings and broader market uncertainty.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune Group Inc. is trending as the FDA accepted its resubmitted Biologics License Application for the RP1/Opdivo combination in advanced melanoma, setting an April 2026 PDUFA date and signaling a potential reversal of prior regulatory setbacks. The community is buzzing, with many viewing this as validation of RP1's strong clinical data despite previous bureaucratic hurdles, while others remain cautious about the long road to final approval and potential for price volatility.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing is trending amidst community chatter around a significant rumored aircraft order from China and increased defense spending driven by global geopolitical tensions, reinforcing its substantial backlog. Sentiment suggests a strengthening recovery narrative if the stock can overcome current resistance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Enlightify, Inc. engages in the research, development, production, and sale of various types of fertilizers and agricultural products. It operates through the following segments: Jinong, Gufeng, Yuxing, and Antaeus. The Jinong and Gufeng segments refer to fertilizer production. The Yuxing segment includes agricultural products. The Anteus segment involves Bitcoins. The company was founded by Tao Li on February 6, 1987 and is headquartered in Xi'an, China.

ENFY
Enlightify Inc.

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest ENFY News

ENFYEnlightify Inc.